How do clinical tools guide tigecycline usage?

How do clinicians decide whether tigecycline is the right choice?

Clinicians weigh tigecycline when standard agents are ruled out by resistance patterns or patient allergies. The drug covers many multidrug-resistant gram-negative and gram-positive organisms, but it lacks reliable activity against Pseudomonas or Proteus, so local antibiograms are checked first.

What dosing and monitoring steps are used in practice?

A 100 mg intravenous loading dose followed by 50 mg every 12 hours is standard for most infections. In severe cases or high-volume distribution states, some centers increase the maintenance dose to 100 mg twice daily. Liver-function tests are checked at baseline and periodically because tigecycline clearance drops in hepatic impairment, and dose reduction is advised when bilirubin exceeds three times the upper normal limit.

How is efficacy tracked during therapy?

Daily assessment of fever, white-cell count, and inflammatory markers guides continuation. Repeat cultures are obtained when feasible to confirm pathogen clearance, especially in ventilator-associated pneumonia or complicated intra-abdominal infections. If clinical response stalls after 72 hours, therapy is reassessed for source control issues or superinfection.

When are susceptibility reports required before starting?

Empiric use is limited to institutions where local resistance data show high rates of carbapenem-resistant Enterobacterales. Once the organism is identified, susceptibility results must confirm an MIC ≤0.5 µg/mL for tigecycline before de-escalation decisions are finalized.

What safety signals prompt early discontinuation?

Nausea and vomiting are common; antiemetics and slower infusion rates can mitigate them. More concerning signals include rising bilirubin or new coagulopathy, both of which trigger prompt review. The FDA boxed warning for excess mortality in ventilator-associated pneumonia is reviewed with every case, and alternative agents are chosen if Pseudomonas is possible.

How does tigecycline fit into stewardship programs?

Antimicrobial stewardship teams review every tigecycline order within 24 hours to confirm that narrower options have been exhausted. Automatic stop dates at 7–14 days and prospective audit reduce unnecessary prolonged courses and preserve the drug for documented multidrug-resistant infections.

When does the patent on tigecycline expire?

The composition-of-matter patent for tigecycline expired in 2015; several generic versions are now marketed. Additional method-of-use patents on specific resistant indications remain in force in certain jurisdictions through 2029, which can affect formulary decisions at some hospitals.